Payment overview · 2025
General Payments
$146.47
8 reported records · 7 companies
Healthcare provider profile · identity verified
Intisab Sultan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SELMA, CA · NPI 1548362296
Verified facts
What the public records show
CMS Open Payments records show Intisab Sultan, M.D. received $146.47 in general payments during 2025 across 8 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.05 | 19.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.11 | 18.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.58 | 16.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.59 | 14.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.15 | 11.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.18 | 9.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.81 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.47 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 163 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 835 | 233 |
| Metoprolol Succinate | Metoprolol Succinate | 424 | 114 |
| Metformin Hcl | Metformin Hcl | 410 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 255 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 72 |
| Lisinopril | Lisinopril | 236 | 68 |
| Gabapentin | Gabapentin | 227 | 63 |
| Ibuprofen | Ibuprofen | 190 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 181 | 31 |
| Omeprazole | Omeprazole | 171 | 48 |
| Losartan Potassium | Losartan Potassium | 165 | 51 |
| Jardiance | Empagliflozin | 163 | 36 |
| Tramadol Hcl | Tramadol Hcl | 155 | 41 |
| Furosemide | Furosemide | 135 | 37 |
| Ozempic | Semaglutide | 121 | 26 |
| Glimepiride | Glimepiride | 120 | 32 |
| Alendronate Sodium | Alendronate Sodium | 119 | 34 |
| Naproxen | Naproxen | 107 | 48 |
| Valsartan | Valsartan | 107 | 32 |
| Donepezil Hcl | Donepezil Hcl | 100 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 37 |
| Farxiga | Dapagliflozin Propanediol | 98 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 29 |
| Allopurinol | Allopurinol | 95 | 27 |
| Xarelto | Rivaroxaban | 95 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 24 |
| Potassium Chloride | Potassium Chloride | 86 | 28 |
| Pregabalin | Pregabalin | 84 | 20 |
| Carvedilol | Carvedilol | 80 | 20 |
| Alprazolam | Alprazolam | 79 | 20 |
| Finasteride | Finasteride | 78 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 16 |
| Eliquis | Apixaban | 71 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 67 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 41 |
| Chlorthalidone | Chlorthalidone | 64 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 15 |
| Trazodone Hcl | Trazodone Hcl | 59 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 20 |
| Memantine Hcl | Memantine Hcl | 57 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Mirtazapine | Mirtazapine | 50 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 13 |
| Simvastatin | Simvastatin | 48 | 14 |
| Lorazepam | Lorazepam | 45 | 11 |
| Montelukast Sodium | Montelukast Sodium | 45 | 16 |
| Dutasteride | Dutasteride | 43 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 27 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 12 |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 26 |
| Clonidine Hcl | Clonidine Hcl | 28 | 13 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Linzess | Linaclotide | 27 | 13 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Diazepam | Diazepam | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Prednisone | Prednisone | 24 | 14 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | 11 |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.47 · 8 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ACCRUFER, JARDIANCE, OTEZLA, Ozempic, REPATHA, TEZSPIRE, TRELEGY ELLIPTA, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error